Blueprint Medicines (BPMC) Misses Q4 EPS by 7c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines (BPMC) Misses Q4 EPS by 7c, Revenues Miss

Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results

February 26, 2019 7:02 AM EST

CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2018.

"Following a year of remarkable clinical progress across our portfolio in 2018, we are focused on executing our '2020 Blueprint' vision to transform... More